Bristol Myers Squibb Company
BMY Healthcare Drug Manufacturers General
Bristol Myers Squibb Company’s revenue for fiscal 2025 (year ended December 2025) was $48.2 billion, roughly unchanged from fiscal 2024. In the quarter to June 2026, revenue grew 5.74%, EPS grew 153.1%, free cash flow fell 13.2% and total debt fell 12.3%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for twenty-five consecutive years.
Follow BMY
Bristol Myers Squibb Company (BMY) Free cash flow
Bristol Myers Squibb Company's free cash flow for fiscal 2025 was $12.8B, down 7.87% from $13.9B in fiscal 2024. Over the twelve months to 30 June 2026 it was $11.4B. Over the past ten years it has ranged from $1.3B (fiscal 2015) to $15.2B (fiscal 2021); the current reading is higher than 73% of that period. Bristol Myers Squibb Company ranks 8th of 21 Drug Manufacturers General companies by free cash flow.
Free cash flow, annual
Embed this chart
Annual newest first
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | $12.8B | (7.87%) |
| FY2024 | $13.9B | 10.20% |
| FY2023 | $12.7B | 5.88% |
| FY2022 | $11.9B | (21.57%) |
| FY2021 | $15.2B | 14.55% |
| FY2020 | $13.3B | 80.35% |
| FY2019 | $7.4B | 20.59% |
| FY2018 | $6.1B | 44.91% |
| FY2017 | $4.2B | 128.97% |
| FY2016 | $1.8B | 43.42% |
Quarterly newest first
| Period | Free cash flow | Change |
|---|---|---|
| Jun 2026 | $3.1B | 307.93% |
| Mar 2026 | $757.0M | (52.81%) |
| Dec 2025 | $1.6B | (73.23%) |
| Sep 2025 | $6.0B | 68.48% |
| 42 more quarters | Free account |
Against its own ten years
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| NVS Novartis AG compare | $15.2B |
| SNY Sanofi compare | $14.5B |
| GILD Gilead Sciences, Inc. compare | $12.9B |
| BMY Bristol Myers Squibb Company | $11.4B |
| PFE Pfizer Inc. compare | $11.0B |
| AMGN Amgen Inc. compare | $10.2B |
| GSK GSK PLC Sponsored ADR compare | $7.6B |
| NVO Novo Nordisk A/S compare | $7.6B |
| AZN AstraZeneca PLC compare | $6.3B |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)
More on BMY
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement